Chikungunya virus entry is strongly inhibited by phospholipase A2 isolated from the venom of *Crotalus durissus terrificus*

Igor Andrade Santos1, Jacqueline Farinha Shimizu1,2, Débora Moraes de Oliveira1, Daniel Oliveira Silva Martins1,2, Léia Cardoso-Sousa3, Adélia Cristina Oliveira Cintra3, Victor Hugo Aquino1, Suely Vilela Sampaio1, Nilson Nicolau-Junior4, Robinson Sabino-Silva1, Andres Merits5, Mark Harris6 & Ana Carolina Gomes Jardim1,2

Chikungunya virus (CHIKV) is the etiologic agent of Chikungunya fever, a globally spreading mosquito-borne disease. There is no approved antiviral or vaccine against CHIKV, highlighting an urgent need for novel therapies. In this context, snake venom proteins have demonstrated antiviral activity against several viruses, including arboviruses which are relevant to public health. In particular, the phospholipase A2cb (PLA2cb), a protein isolated from the venom of *Crotalus durissus terrificus* was previously shown to possess anti-inflammatory, antiparasitic, antibacterial and antiviral activities. In this study, we investigated the multiple effects of PLA2cb on the CHIKV replicative cycle in BHK-21 cells using CHIKV-nanoluc, a marker virus carrying nanoluciferase reporter. The results demonstrated that PLA2cb possess a strong anti-CHIKV activity with a selectivity index of 128. We identified that PLA2cb treatment protected cells against CHIKV infection, strongly impairing virus entry by reducing adsorption and post-attachment stages. Moreover, PLA2cb presented a modest yet significant activity towards post-entry stages of CHIKV replicative cycle. Molecular docking calculations indicated that PLA2cb may interact with CHIKV glycoproteins, mainly with E1 through hydrophobic interactions. In addition, infrared spectroscopy measurements indicated interactions of PLA2cb and CHIKV glycoproteins, corroborating with data from in silico analyses. Collectively, this data demonstrated the multiple antiviral effects of PLA2cb on the CHIKV replicative cycle, and suggest that PLA2cb interacts with CHIKV glycoproteins and that this interaction blocks binding of CHIKV virions to the host cells.

Chikungunya virus (CHIKV), a member of the genus *Alphavirus*, family *Togaviridae*, is the causative agent of Chikungunya fever2. CHIKV virions comprise an icosahedral capsid with a positive single stranded RNA genome of approximately 12 kb3 surrounded by a lipid envelope with E1, E2 and E3 glycoproteins in its surface4,5. CHIKV was first identified in 1950 in Tanzania, Africa and related to Chikungunya fever in 19556,7. CHIKV is transmitted through the bite of *Aedes aegypti* and *Aedes albopictus* mosquito8,9, and, therefore, have been associated to the epidemics in tropical and subtropical regions10. Since then, CHIKV outbreaks have been identified in many regions including islands of Indian Ocean, India, South-East Asia, France, Italy and the Americas11. In Brazil, the first cases of Chikungunya fever were documented in 2014, and since then, the disease became an endemic12. From January to June of 2020, 48,316 cases and 11 deaths by CHIKV were notified13. Chikungunya fever symptoms include fever, nausea, fatigue, arthralgia and polyarthralgia14. In some rare cases, infected individuals can develop hepatitis, myocarditis, and encephalopathy, ultimately leading to death.
of patients\(^{14,15}\). Unlike other arboviruses, CHIKV infection can result in chronic symptoms lasting for months or years, resulting in a disabling disease\(^{16,17}\). There are no approved antiviral drugs against CHIKV infection, as a consequence the treatment is often palliative and symptomatic, based on analgesics, non-steroidal anti-inflammatory, rest, and hydration\(^{18}\).

Given that many approved drugs employed in the treatment of infectious and chronic diseases originated or derived from natural sources\(^{19,20}\), it is reasonable to hypothesize that natural compounds may also be exploited to generate antiviral drugs. In this context, proteins isolated from snake venoms represent promising drug leads, since they are a complex mixture of lectins, oxidases, disintegrins, metalloproteins, and phospholipases A2 (PLA2s)\(^{21,22}\). From these, PLA2s, in its turn, are members of a secreted phospholipases, which can act in the cell membranes and play several roles in biological systems\(^{23–25}\).

The snake venom isolated from Crotalus durissus terrificus has numerous constituents such as crotoxin, crotamin, neurotoxin, among others\(^{26,27}\). Crotoxin is the major constituent of the C. d. terrificus venom. It is characterized as a protein complex composed by two noncovalent subunits, the basic subunit phospholipase A2 (PLA2CB), and the acid subunit crotapotin\(^{28,29}\). Subsequently, PLA2CB is approximately 14 kDa protein which possess anti-inflammatory, antiparasitic, and antibacterial properties\(^{30,31}\). PLA2CB has also presented activity towards viruses such as hepacivirus C (HCV)\(^{32}\), Rocio (ROCV), Mayaro (MAYV), Dengue (DENV) and Yellow Fever (YFV)\(^{33,34}\). Russo and coworkers expressed and purified two recombinant PLA2CB (rPLA2CB) and partially assessed its anti-CHIKV activity. It was found that rPLA2CB proteins possess lower antiviral activity and higher cytotoxicity profile than the native protein, probably due to nine additional amino acid residues present in their sequences\(^{35}\). Considering these previous results, herein we performed thorough in vitro evaluation of the effects of the native PLA2CB on the CHIKV replication cycle.

Results

**PLA2\(_{CB}\) strongly impairs CHIKV infection in vitro.** We investigated the anti-CHIKV activity of the PLA2\(_{CB}\) (Fig. 1A) using BHK-21 cells and a recombinant CHIKV that expresses a nanoluciferase reporter (CHIKV-\textit{nanoluc}) (Fig. 1B)\(^{36,37}\). First, the PLA2\(_{CB}\) antiviral activity was evaluated by performing a dose–response assay to determine the effective concentration of 50% (EC\(_{50}\)) and cytotoxicity of 50% (CC\(_{50}\)). BHK-21 cells were infected with CHIKV-\textit{nanoluc} and simultaneously treated with PLA2\(_{CB}\) at concentrations ranging from 0.195 to 200 µg/mL in two-fold serial dilutions, and viral replication was assessed 16 h post-infection (h.p.i.) (Fig. 1C). In parallel, cell viability was assessed by an MTT assay. PLA2\(_{CB}\) was found to be able to inhibit virus replication to greater than 99%, while the cell viability at the highest concentration tested was 43%. It was determined that PLA2\(_{CB}\) has the EC\(_{50}\) of 1.34 µg/mL, CC\(_{50}\) of 172 µg/mL, and the Selectivity Index (SI) of 128 (Fig. 1D). Thus, PLA2\(_{CB}\) acts as strongly inhibitor of CHIKV infection with high SI value.
PLA2 CB strongly inhibits early stages of CHIKV infection. Time-of-addition type of experiments were used to analyze the effect of PLA2 CB on different stages of CHIKV replication. For all of these assays, cells were treated with PLA2 CB at 12.5 µg/mL, a concentration that inhibited virus replication by ~ 91% without affecting cell viability (Fig. 1D).

To assess the protective effects of PLA2 CB against CHIKV infection, cells were pretreated with PLA2 CB for 1 h at 37 °C, washed extensively with PBS to remove the compound and infected with CHIKV-nanoluc for 1 h. Then, the supernatant was removed, cells were added of fresh medium and luciferase levels were measured 16 h.p.i. PLA2 CB significantly reduced CHIKV-nanoluc infection by 84% (p < 0.01), demonstrating a robust protective effect (Fig. 2A). The protective effect did not increase when the compound was present for all duration of the experiment (Fig. 2B), demonstrating that pre-treatment of cells with PLA2 CB inhibited CHIKV replication. This data suggests that PLA2 CB acts by protecting cells against infection and/or by affecting early stages of CHIKV infection.

To further evaluate the PLA2 CB effect on CHIKV entry to the host cells, virus and PLA2 CB were simultaneously added to BHK-21 cells for 1 h at 37 °C, cells were washed with PBS and replaced with fresh medium (Fig. 3A). PLA2 CB demonstrated to decrease 95.3% of CHIKV replication (p < 0.0001), indicating that this compound strongly inhibited the CHIKV-nanoluc entry (Fig. 3A). Combining this treatment with a 1 h pre-incubation of the inoculum containing PLA2 CB and CHIKV at 37 °C further increased inhibition that reached over 99% (Fig. 3B), indicating that PLA2 CB also possesses virucidal activity. To analyze the effect of PLA2 CB on CHIKV attachment, virus and compound were first incubated with the cells at 4 °C for 1 h. At this temperature, virus particles were able to attach to the cellular receptors, but not entry into the host cells. Cells were then washed with PBS, fresh medium added, and incubated at 37 °C (Fig. 3C), to allow the continuation of the entry process. Data obtained from this assay also showed strong inhibition of CHIKV attachment by reducing virus entry by 98.2% to the cells (p < 0.0001) (Fig. 3C). Post-attachment was evaluated by including an additional incubation of 30 min at 37 °C to the previous protocol (Fig. 3D), showing that the inhibition reminded strong reaching 95.2% (p < 0.0001) (Fig. 3D). Taken together this data indicates that PLA2 CB possesses a robust virucidal activity and the ability to block virus entry to host cells.

PLA2 CB moderately affect post-entry steps of CHIKV infection. Two assays were used to analyze effects of PLA2 CB on post-entry stages of CHIKV infection. Using CHIKV-nanoluc it was found that, if added after virus infection, compound cause relatively modest, 64% reduction of CHIKV replication (p < 0.0001).
(Fig. 4A). To reveal the effect of PLA2CB on virus RNA replication in the absence of production and spread of virions, BHK-CHIKV-NCT cells were used. This stable cell line contains CHIKV replicon which continuously expresses viral nonstructural proteins and two reporters: Renilla luciferase from nonstructural region and EGFP via activity of viral subgenomic promoter. Measurement of activities of these reporters allows the evaluation of the effect of PLA2CB on replication complexes formed during the replication stage as well as on production and translation of subgenomic RNAs. Treatment of BHK-CHIKV-NCT cells with PLA2CB at 12.5 µg/mL for 72 h after treatment revealed the reduction of Renilla luciferase expression by 58% without causing detectable cytotoxicity (Fig. 4B); this data confirms observation made using CHIKV-nanoluc. Furthermore, the levels in EGFP expression were also reduced as seen in Fig. 4C, indicating decrease of subgenomic RNA synthesis and/or translation. Taken together, these results suggest that PLA2CB inhibits post-entry stages of infection possibly interfering with functioning of CHIKV nonstructural proteins.

Molecular docking reveals possible interactions between PLA2CB and CHIKV glycoproteins. Results of inhibition assays clearly demonstrate that PLA2CB inactivates CHIKV virions and impairs their binding to host cell suggesting interaction of compound with outer surface of virion. Therefore, a molecular docking assay was performed to investigate interactions and reveal potential binding mode between PLA2CB and CHIKV glycoproteins. In a blind molecular docking, PLA2CB was predicted to interact with the E1 and E2 of the glycoprotein complex, with global energy of −0.57 kJ/mol after refining (Fig. 5).

The 2D interactions between PLA2CB and CHIKV glycoproteins showed that PLA2CB mainly interacts with E1 glycoprotein, forming thirty hydrophobic interactions (residues Ile63, Gln33, Pro19, Phe109, Gly31, Ala55, Val18, Lys60, Arg114, Phe23, Trp30, Trp61, Leu3 in PLA2CB and residues Gln353, Lys132, Leu34, Val269, Ser35, Asn389, Arg134, Asn140, Tyr390, Leu136, Gln260, Gly12, He344, Glu32, Arg340, Ser355 in E1 glycoprotein) (Fig. 6). Also, PLA2CB formed 3 hydrogens bonds with E1, Ser113 and Asn270 (2.30 Å), Asn58 and Glu343 (2.95 Å) and His1 and Glu341 (2.18 Å) (Fig. 6). PLA2CB may also form one hydrogen bond with E2 glycoprotein (between Arg11 and Glu 334 (2.07 Å), plus five hydrophobic interactions (Asn105, Lys104, Gly106 in PLA2CB and Asn273, Lys270 in E1) (Fig. 7).

PLA2CB causes molecular changes in CHIKV glycoprotein. To further investigate the interactions between PLA2CB and CHIKV particles, infrared spectroscopy spectral analysis and vibrational analysis among the virus and PLA2CB was performed. Representative means of the infrared spectrum of CHIKV, PLA2CB, and CHIKV plus PLA2CB, which is the bio fingerprint region representing proteins, lipids, nucleic acids, and glycoproteins are shown in Fig. 8A. A representative infrared average spectrum of second derivative analysis from CHIKV virions, PLA2CB, and CHIKV virions plus PLA2CB is displayed in Fig. 8A. In the second derivative
Figure 4. PLA2CB inhibits post-entry stage of CHIKV. (A) BHK-21 cells were infected with CHIKV-nanoluc (MOI 0.1) for 1 h, washed to remove unbound virus and added of medium containing PLA2CB at 12.5 μg/mL for 16 h. Nanoluciferase levels were measured to access CHIKV-nanoluc replication rates. (B) BHK-CHIKV-NCT cells were seed 24 h prior treatment and treated with PLA2CB at 12.5 μg/mL for 72 h. Renilla luciferase activity and cellular viability measured. (C) Fluorescence of untreated control and PLA2CB treatment in BHK-CHIKV-NCT, observed in fluorescence microscopy using 20 × lens (scale bar 400 μm), in GFP filter. Schematic representation of each assay as indicated by BHK-21 cells or BHK-CHIKV-NCT (black bars), PLA2CB (grey bars), and CHIKV-nanoluc (blue bars). Mean values ± SD of a minimum of three independent experiments each measured in triplicate. (****) P < 0.0001. All images were generated using GraphPad Prism 8 and GIMP 2.10.20 (www.gimp.org).

Figure 5. Molecular docking suggests possible interactions between PLA2CB and CHIKV glycoproteins. The post-docking 3D image was generated in the DS Visualizer program (Dassault Systèmes BIOVIA, Discovery Studio Visualizer, 2016). The CHIKV envelope glycoproteins E1 (Red), E2 (Blue), E3 (green), complexed with PLA2CB (purple) are shown. All images were generated using GraphPad Prism 8 and GIMP 2.10.20 (www.gimp.org).
analysis, the value heights indicate parallel changes in the intensity of each functional group. The binding interaction between CHIKV virions and PLA2CB was mainly revealed by the increase in the vibrational mode at 1068 cm$^{-1}$, which indicates detection of additional stretching of C-O ribose present in glycoprotein derived from the association CHIKV virions and PLA2CB (Fig. 8B). Furthermore, the Stacked Walls (Fig. 9A) and split heat map (Fig. 9B) reinforces the additional expression of vibrational mode at 1068 cm$^{-1}$ under CHIKV virions plus PLA2CB association.

**Discussion**

Natural PLA2CB has shown to have broad spectrum antiviral activity$^{32-34}$. Here, we assessed the antiviral activity of the PLA2CB against CHIKV, as well as sought comprehension on its mechanism of action. Our results demonstrated that PLA2CB strongly inhibited CHIKV infection, corroborating with Russo and colleagues work, which demonstrated that rPLA2CB impaired CHIKV infection$^{35}$. Additionally, the results demonstrated that the pre-treatment of naïve cells with PLA2CB protected host cells against CHIKV infection. In accordance with our study, Chen and coworkers have reported that phospholipase A2 isolated from the venom of the honeybee Apis mellifera was able to protect cells against Human immunodeficiency virus (HIV) and dengue virus (DENV) infections$^{41}$. Fenard and colleagues also demonstrated that cells can be protected against HIV infection by different phospholipases A2 isolated from several mammalian species$^{42}$. The PLA2s from snake venoms are classified...
in the group II of a secreted family phospholipases and show homology to the mammalian inflammatory PLA2, which play different roles in the organism including in an immune response to infectious diseases. Therefore, our data might also suggest that PLA2 plays a role in host cell metabolism and as a result protects cells against viral infection, by the possible mimicking effect of phospholipases found in host cells.

**Figure 8.** Infrared spectroscopy. Spectral analysis indicates interactions between CHIKV virion and PLA2. (A) Representative infrared average spectrum of second derivative analysis from PLA2 (red line), CHIKV virion (black line), and PLA2 plus CHIKV virion (blue line) employing an Fourier Transform Infrared (FTIR) methodology. (B) Second derivative analysis, which the value heights indicate the intensity of each functional group. All images were generated using GraphPad Prism 8 and GIMP 2.10.20 (www.gimp.org).

**Figure 9.** Infrared spectroscopy. Spectral analysis between CHIKV virion and PLA2. A representative Stacked Walls (A) and split heat map (B) of the infrared average spectrum of second derivative analysis from PLA2 (red), CHIKV virions (black), and PLA2 plus CHIKV virions (blue). All images were generated using GraphPad Prism 8 and GIMP 2.10.20 (www.gimp.org).
Our findings that PLA2$_{cb}$ has strong virucidal effect and interferes with viral entry to the host cells are consistent with previous findings made for two flaviviruses, DENV and yellow-fever (YFV)$^{34}$. The authors demonstrated that incubation of DENV or YFV virions with PLA2$_{cb}$ results in inhibition of early steps of viral infection probably by disrupting virion envelope membrane and/or blocking virus adsorption$^{33,34}$. Additionally, Russo and coworkers described that incubation of PLA2$_{cb}$ with CHIKV prior to the infection of cells significantly impaired CHIKV infectivity$^{35}$. Therefore, our results are in agreement with previous data that suggested that the predominant activity of PLA2$_{cb}$ is due to its virucidal effect, probably by acting on the virus particle. Several PLA2s isolated from snake venom have been described to possess antiviral activity against DENV, YFV, Herpes simplex types 1 and 2 and Influenza A (H3N2) by interacting with lipid membrane found in a pocket between glycoproteins and/or through attachment to the glycoproteins in the viral envelope surface$^{33,34,41,47}$. Based on this data, we performed a blind molecular docking using PLA2$_{cb}$ and the CHIKV glycoproteins complex (E1, E2, and E3) to assess the possible interaction among them. The results demonstrated that PLA2$_{cb}$ most likely bonded to both E1 and E2 with E1 being the main target. These results are also consistent with the virucidal effect described here and corroborate previously published data$^{39}$. The glycoproteins E1 and E2 are essential during the early stages of CHIKV infection. The CHIKV glycoprotein E2 is responsible for binding to cells receptors such as MXRA48; the binding occurs in the "canyon" between protomers of CHIKV spike complex. In addition, impaired CHIKV infectivity$^{35}$. Therefore, our results are in agreement with previous data that suggested that similarities and differences between anti-HCV and anti-CHIKV effects represent topics for additional studies.

To produce CHIKV-BHK21 cells were seeded in each of wells of a 24 wells plate; 24 h later the cells were infected with tenfold serially dilutions of 1.5 μg of CHIKV-CMV-nanoluc plasmid using Lipofectamine 2000 and Opti-Mem medium. 48 h post-transfection (h.p.t.) the supernatant was collected and stored at −80°C. To determine viral titers, 1 × 10$^5$ BHK-21 cells seeded in a T175 cm$^2$ flask were transfected with plasmid using Lipofectamine 2000 and Opti-Mem medium. 48 h post-transfection (h.p.t.) the supernatant was collected and stored at −80°C. To determine viral titers, 1 × 10$^5$ BHK-21 cells were seeded in each of wells of 24 wells plate; 24 h later the cells were infected with tenfold serial dilutions of NA

The crude venom of Crotalus durissus terrificus was obtained from the "Animal Toxin Extraction Center" (CETA), duly registered and approved by the Ministry of the Environment under de process number 3002678. The venom was collected from 28 specimens from the Morungaba—SP collection under the Brazilian Institute for the Environment and Renewable Natural Resources (IBAMA) authorization: 1/35/1998/000846–1, and extraction was performed by Jairo Marques do Vale (CETA). All experiments were performed in accordance with relevant named guidelines and regulations available in the federal universities, IBAMA and the Ministry of Environment. The isolation and purification of phospholipase PLA2$_{cb}$ (Fig. 1A) from the venom of Crotalus durissus terrificus snakes were carried out at the Toxinology Laboratory of the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, as previously described$^{28,34}$. The lyophilized protein was dissolved in PBS (phosphate buffer saline), filtered, and stored at -80°C. Dilutions of the stock solution containing the protein were made immediately prior to the experiments. For all the performed assays, PBS was used as the untreated control. All authors complied with the ARRIVE guidelines.

In summary, our study evidenced that PLA2$_{cb}$ isolated from Crotalus durissus terrificus inhibited multiple steps of CHIKV infection. The enzyme was able to protect the target cells against CHIKV infection, impaired virus entry to the host cells, mainly by virucidal activity, and also disturbed post-entry steps of the CHIKV infection. Therefore, this data might be useful for further development of new antiviral approaches against CHIKV and provide the potential for treatment of Chikungunya fever.

**Methods**

**Compound.** The crude venom of Crotalus durissus terrificus was obtained from the "Animal Toxin Extraction Center" (CETA), duly registered and approved by the Ministry of the Environment under de process number 3002678. The venom was collected from 28 specimens from the Morungaba—SP collection under the Brazilian Institute for the Environment and Renewable Natural Resources (IBAMA) authorization: 1/35/1998/000846–1, and extraction was performed by Jairo Marques do Vale (CETA). All experiments were performed in accordance with relevant named guidelines and regulations available in the federal universities, IBAMA and the Ministry of Environment. The isolation and purification of phospholipase PLA2$_{cb}$ (Fig. 1A) from the venom of Crotalus durissus terrificus snakes were carried out at the Toxinology Laboratory of the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, as previously described$^{28,34}$. The lyophilized protein was dissolved in PBS (phosphate buffer saline), filtered, and stored at -80°C. Dilutions of the stock solution containing the protein were made immediately prior to the experiments. For all the performed assays, PBS was used as the untreated control. All authors complied with the ARRIVE guidelines.

**Cell culture.** BHK-21 cells (fibroblasts derived from Syrian golden hamster kidney; ATCC CCL-10), purchased from The Global Bioresource Center (ATCC), were maintained in Dulbecco's modified Eagle's medium (DMEM, SIGMA-ALDRICH) supplemented with 100 μg/mL of penicillin (HYCLONE LABORATORIES), 100 mg/mL of streptomycin (HYCLONE LABORATORIES), 1% dilution of stock of non-essential amino acids (HyClone Laboratories) and 1% of fetal bovine serum (FBS, HYCLONEN LABORATOIRES) in a humidified 5% CO$_2$ incubator at 37°C. Subgenomic replicon (SGR) harboring cell lines (BHK-CHIKV-NCT) were maintained under the same conditions of BHK-21 cells (ATCC CCL-10), except for the addition of G418 (SIGMA-ALDRICH) at 5 mg/mL.

**Rescue of CHIKV-nanoluc reporter virus.** The CHIKV expressing nanoluciferase reporter (CHIKV-nanoluc) (Fig. 1B) used for the antiviral assays is based on the CHIKV isolate LR2006OPY1 (East/Central/South African genotype). The infectious cDNA of CHIKV-nanoluc was placed under control of the CMV promoter$^{46}$. To produce CHIKV-nanoluc virions, 2.3 × 10$^7$ BHK-21 cells seeded in a T175 cm$^2$ flask were transfected with 1.5 μg of CHIKV-CMV-nanoluc plasmid using Lipofectamine 2000 and Opti-Mem medium. 48 h post-transfection (h.p.t.) the supernatant was collected and stored at −80°C. To determine viral titers, 1 × 10$^5$ BHK-21 cells were seeded in each of wells of 24 wells plate; 24 h later the cells were infected with tenfold serial dilutions of CHIKV,nanoluc.
CHIKV-nanoluc. Cells were incubated with virus for 1 h 37 °C; after this, the inoculums were removed, cells were washed with PBS to remove the unbound virus, and fresh medium supplemented with 1% dilution of stock of penicillin and streptomycin, 2% FBS and 1% carboxymethyl cellulose (CMC) was added. Infected cells were incubated for 2 days in a humidified 5% CO2 incubator at 37 °C, followed by fixation with 4% formaldehyde and staining with 0.5% violet crystal. The viral foci were counted to determine viral titre which was presented in plaque forming units per milliliter (PFU/mL).

Cell viability assay. Cell viability was measured by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (SIGMA-ALDRICH) assay as previously described53. BHK-21 cells were plated to 48 well plates at a density of 5 × 104 cells per well and incubated overnight at 37 °C. Medium containing two-fold serial dilutions of PLA2CB (from 0.195 to 200 µg/mL) was added and cells were incubated for 16 h. After this, the medium was replaced with the MTT solution at 1 mg/mL, cells were incubated for 30 min, after which MTT solution was and replaced with 300 µL of DMSO (dimethyl sulfoxide) to solubilize the formazan crystals. The absorbance was measured at 490 nm on the Glomax microplate reader (PROMEGA). Cell viability was calculated according to the equation (T/C) ×100%, where T and C represent the mean optical density of the treated and untreated control groups, respectively. The cytotoxic concentration of 50% (CC50) was calculated using GraphPad Prism 8.

Determination of the effective concentration 50% (EC50). To assess the antiviral activity of PLA2CB, BHK-21 cells were seeded at a density of 5 × 104 cells per well into 48 well plates for 24 h and infected with CHIKV-nanoluc at a multiplicity of infection (MOI) of 0.1 PFU/cell as described by Oliveira and coworkers55. The PLA2CB at concentrations ranging 0.195–200 µg/mL was added to growth media. Samples were harvested using Renilla-luciferase lysis buffer (PROMEGA) at 16 h post-infection (h.p.i.) and virus replication levels were quantified by measuring nanoluciferase activity using the Renilla luciferase Assay System (PROMEGA). The effective concentration of 50% inhibition (EC50) was calculated using GraphPad Prism 8 software. The values of CC50 and EC50 were used to calculate the selectivity index (SI = CC50/EC50).

Time-of-addition assays. BHK-21 cells at the density of 5 × 104 cells per well were seeded in 48 well plates 24 h before infection and treatment. All infections were performed at MOI of 0.1 and efficiency of virus replication was assessed by measurement of nanoluciferase activity at 16 h.p.i.

In pretreatment assay, cells were treated for 1 h with the compound prior to the CHIKV infection, extensively washed with PBS and added of CHIKV-nanoluc for 1 h. Then, cells were washed with PBS and incubated to remove unbound virus and added of fresh medium for 16 h (Fig. 2A). Alternatively, cells were treated for 1 h with the compound, washed with PBS and infected with CHIKV-nanoluc at the presence (Fig. 2B) of PLA2CB for 16 h. In entry inhibition assay, cells were infected using media containing the compound– and virus for 1 h, washed with PBS and incubated with fresh medium for 16 h (Fig. 3A). The virucidal activity was assessed using the same setting except inoculum containing compound and virus was incubated for 1 h before it was added to the cells (Fig. 3B). The impact of compound on attachment step was analyzed using the same setting as in entry inhibition assay except compound and virus was added with compound and virus at 4 °C (Fig. 3C). A variant of this assay where the incubation at 4 °C was followed by incubation for 30 min at 37 °C was used to analyze the effect of compound on post-attachment steps of infection (Fig. 3D).

In post-entry assay, cells were infected with CHIKV for 1 h, washed extensively with PBS, and the incubated in compound-containing medium for 16 h (Fig. 4A).

RNA replication assay using BHK-CHIKV-NCT cells. BHK-CHIKV-NCT cells that express CHIKV nonstructural proteins, a selection marker (puromycin acetyltransferase, Pac) and Renilla luciferase and EGFP reporters57, were used to assess the activity of PLA2CB on CHIKV RNA replication. Cells were seeded at a density of 7 × 104 cells per well of a 96 well plate. After 24 h, cells were treated with the PLA2CB at 12.5 µg/mL for 72 h (Fig. 4B). The impact of compound on CHIKV RNA replication was estimated by quantification of Renilla luciferase expression. In addition, EGFP fluorescence was monitored by placing plates directly using an EVOS (THERMO-FISCHER) fluorescence microscope and using 20 × lens and GFP filter.

Molecular docking analysis. The interaction between PLA2CB (PDB: 3R0L) and the envelope glycoproteins of the CHIKV (PDB: 3N42) was analyzed using blind docking performed in the PatchDock server57, using the parameters predefined by the program and refined by the FireDock algorithm57. The best docking positions were evaluated by the geometric complementarity score defined by PatchDock, with results refined and ranked by the global energy after refinement. The post-docking 3D image was generated in the DS Visualizer program, Dassault Systèmes BIOVIA, Discovery Studio Visualizer, version 17, San Diego: Dassault Systèmes, 2016, and a 2D diagram of the interactions interface between the molecules was generated with the aid of the LigPlot + program58.

Infrared spectroscopy spectral data analysis. An Fourier Transform Infrared (FTIR) spectrophotometer Vertex 70 (BRUKER OPTICS, REINSTETTEN, Germany) connected to a micro-attenuated total reflectance (ATR) platform was used to record sample signature at 1800 cm−1 to 400 cm−1 regions as described by Oliveira and coworkers55. The ATR unit is composed of a diamond disc as an internal-reflection element. The sample dehydrated pellicle penetration depth ranges between 0.1 and 2 μm and depends on the wavelength, incidence angle of the beam, and the refractive index of ATR-crystal material. The infrared beam is reflected at the interface toward sample in the ATR-crystal. All samples (2µL) were dried using airflow on ATR-crystal for
3 min before sample spectra recorded in triplicate. The air spectrum was used as a background in all ATR-FTIR analysis. Sample spectra and background were taken with 4 cm⁻¹ resolution and 32 scans were performed for analysis. The spectra were normalized employing the vector method and adjusted to rubber band baseline correction. The original data were plotted in the Origin Pro 9.0 (ORIGINLAB, Northampton, MA, USA) software to create the second derivative analysis. The second derivative was obtained by applying the Savitzky-Golay algorithm with polynomial order 5 and 20 points of the window. The value heights indicated the intensity of the functional group evaluated.

### Statistical analysis

Individual experiments were performed in triplicate and all assays were performed a minimum of three times to confirm the reproducibility of the results. GraphPad Prism 8 software was used to assess statistical differences of means of readings using Student’s unpaired t-test or Mann–Whitney tests. P values <0.01 were considered to be statistically significant.

Received: 22 January 2021; Accepted: 6 April 2021
Published online: 22 April 2021

### References

1. Chen, R. et al. ICTV virus taxonomy profile: Togaviridae. *J. Gen. Virol.* 99, 761–762 (2018).
2. Mayer, S. V., Tesh, R. B. & Vasiliak, N. The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers. *Acta Trop.* 166, 155–163 (2017).
3. Burt, E. J. et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. *Lancet Infect. Dis.* 17, e107–e117 (2017).
4. Strauss, J. H. & Strauss, E. G. The alphaviruses: gene expression, replication, and evolution. *Microbiol. Rev.* 58, 491–562 (1994).
5. Yap, M. L. et al. Structural studies of Chikungunya virus maturation. *Proc. Natl. Acad. Sci. U. S. A.* 114, 13703–13707 (2017).
6. Weaver, S. C. & Forrest, N. L. Chikungunya: Evolutionary history and recent epidemic spread. *Antiviral Res.* 120, 32–39 (2015).
7. Mason, P. J. & Haddow, A. J. An epidemic of viral disease in Southern Province, Tanganyika Territory, in 1952–1953. *Trans. R. Soc. Trop. Med. Hyg.* 51, 238–240 (1957).
8. Mavale, M. et al. Venerable transmission of chikungunya virus by Aedes aegypti mosquitoes (Diptera: Culicidae). *Am. J. Trop. Med. Hyg.* 83, 1242–1244 (2010).
9. Ngaooujui, C., Kamgang, B., Kazaatni, M., Paupy, C. & Nakouné, E. Potential of Aedes aegypti and Aedes albopictus populations in the Central African Republic to transmit enzootic chikungunya virus strains. *Parasit. Vectors* 10, 164 (2017).
10. Kraemer, M. U. G. et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. Albopictus. *Elife* 4, (2015).
11. Silva, L. A., Dermody, T. S., Silva, L. A. & Dermody, T. S. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies Find the latest version: Chikungunya virus: epidemiology , replication , disease mechanisms and prospective intervention strategies. 127, 737–749 (2017).
12. Nunes, M. R. T. et al. Emergence and potential for spread of Chikungunya virus in Brazil. *BMC Med.* 13, 102 (2015).
13. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Situação epidemiológica da síndrome congênita associada à infecção pelo vírus Zika em 2020: até a SE 26. *Bol. Epidemiológico* 51, 23–28 (2020).
14. Das, T. et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. *Prog. Neurobiol.* 91, 121–129 (2010).
15. Powers, A. M., Brault, A. C., Tesh, R. B. & Weaver, S. C. Re-emergence of chikungunya and o’nyong-nyong viruses: Evidence for distinct geographical lineages and distant evolutionary relationships. *J. Gen. Virol.* 81, 471–479 (2000).
16. Dupuis-Maguiraga, L. et al. Chikungunya disease: Infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. *PLoS Negl. Trop. Dis.* 6, e1446 (2012).
17. Gardner, J. et al. Chikungunya virus arthritis in adult wild-type mice. *J. Virol.* 84, 8021–8032 (2010).
18. Centers for Disease Control and Prevention. *Guideline for Emerging and Zoonotic Infectious Diseases (NCEZID)*, D. of V-B. D. (DVBD) et al. Symptoms, Diagnosis, & Treatment | Chikungunya virus | CDC. https://www.cdc.gov/chikungunya/symptoms/index.html (2018).
19. Dias, D. A., Urban, S. & Roessner, U. A historical overview of natural products in drug discovery. *Metabolites* 2, 303–336 (2012).
20. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 1981 to 2019. J. *Nat. Prod.* 83, 770–803 (2020).
21. Bailey, P. & Wilce, J. Venom as a source of useful biologically active molecules. *Emerg. Med. Australas.* 13, 28–36 (2001).
22. Villalta-Romero, F. Discovery of small molecule inhibitors for the snake venom metalloprotease BaP1 using in silico and in vitro tests. *Bioorg. Med. Chem. Lett.* 27, 2018–2022 (2017).
23. Burke, J. E. & Dennis, E. A. Phospholipase A2 Biochemistry. *Cardiovasc. Drugs Ther.* 23, 49–59 (2009).
24. Calderon, L. A. et al. Antitumoral activity of snake venom proteins: New trends in cancer therapy. *Biomed Res. Int.* 2014, 1–19 (2014).
25. Filkin, S. Y., Lipkin, A. V. & Fedorov, A. N. Phospholipase superfamily: Structure, functions, and biotechnological applications. *Biochemistry* 85, 177–195 (2020).
26. Schaloske, R. H. & Dennis, E. A. The phospholipase A2 superfamily and its group numbering system. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids* 1761, 1246–1259 (2006).
27. Six, D. A. & Dennis, E. A. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids* 1488, 1–19 (2000).
28. Hendon, R. A. & Fraenkel-Conrat, H. Biological roles of the two components of crototoxin. *Proc. Natl. Acad. Sci. U. S. A.* 68, 1560–1563 (1971).
29. FAURE, G. et al. The origin of the diversity of crototoxin isoforms in the venom of Crotalus durissus terrificus. *Eur. J. Biochem.* 223, 161–164 (1994).
30. Almeida, J. R. et al. CoaTx-II, a new dimeric Lyso49 phospholipase A2 from Crotalus orengus abyssus snake venom with bacte- ricidal potential: Insights into its structure and biological roles. *Toxicon* 120, 147–158 (2016).
31. de Carvalho, A. E. Z. et al. Crotalus durissus rurumia Snake Venom and a Phospholipase A2 Isolated from This Venom Elicit Macrophages to Form Lipid Droplets and Synthesize Inflammatory Lipid Mediators. *J. Immunol. Res.* 2019, 1–12 (2019).
32. Shimizu, I. et al. Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle. *PLoS ONE* 12, e0187857 (2017).
33. Muller, V. D. et al. Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope. *PLoS ONE* 9, 1–10 (2014).
34. Muller, V. D. M. et al. Crototoxin and phospholipases A2 from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses. *Toxicon* 59, 507–515 (2012).
Expression, purification and virucidal activity of two recombinant isoforms of phospholipase A2 from Crotalus durissus terrificus venom. Arch. Virol. 164, 1159–1171 (2019).

36. Matkovic, R. et al. The host DHX9 DExH-Box helicase is recruited to chikungunya virus replication complexes for optimal genomic RNA translation. J. Virol. 93, 1–17 (2018).

37. Pohjala, L. et al. Inhibitors of alphanavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS ONE 6, e28923 (2011).

38. Derenne, A., Derfoufi, K.-M., Cowper, B., Delportie, C. & Goormaghtigh, E. FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutically monoclonal antibodies. Anal. Chem. Acta 1112, 62–71 (2020).

39. Kajehpour, M., Dushnau, J. L. & Vanderkooi, J. M. Infrared spectroscopy used to evaluate glycosylation of proteins. Anal. Biochem. 348, 40–48 (2006).

40. Movasaghi, Z., Rehman, S. & ur Rehman, D. I. Fourier Transform Infrared (FTIR) Spectroscopy of Biological Tissues. Appl. Spectrosc. Rev. 43, 134–179 (2008).

41. Chen, M. et al. Broad-spectrum antiviral agents: secreted phospholipase A2 targets viral envelope lipid bilayers derived from the endoplasmic reticulum membrane. Sci. Rep. 7, 15931 (2017).

42. Fanard, D. et al. Secreted phospholipases A2, a new class of HIV inhibitors that block virus entry into host cells. J. Clin. Invest. 104, 611–618 (1999).

43. Gutiérrez, I. M. & Lomonte, B. Phospholipases A2: Unveiling the secrets of a functionally versatile group of snake venom toxins. Toxicon 62, 27–39 (2013).

44. Murakami, M. et al. The roles of the secreted phospholipase A2 gene family in immunology, in 91–134 (2016). https://doi.org/10.1016/bs.ai.2016.05.001.

45. Palm, N. W. et al. Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. Immunity 39, 976–985 (2013).

46. Sadekuzzaman, M., Stanley, D. & Kim, Y. Nitric oxide mediates insect cellular immunity via phospholipase A2 activation. J. Innate Immun. 10, 70–81 (2018).

47. Brenes, H., Loria, G. D. & Lomonte, B. Potent viral activity against Flaviviridae of a group IIA phospholipase A2 isolated from the venom of Bothrops asper. Biologicals 63, 48–52 (2020).

48. Song, H. et al. Molecular basis of arthritogenic alphavirus receptor MXRA8 binding to chikungunya virus envelope protein. Cell 177, 1714–1724.e12 (2019).

49. Salvador, B., Zhou, Y., Michaült, A., Muench, M. O. & Simmons, G. Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 393, 33–41 (2009).

50. Wengler, G., Koschinski, A., Wengler, G. & Dreyer, F. Entry of alphanviruses at the plasma membrane converts the viral surface proteins into an ion-permeable pore that can be detected by electrophysiological analyses of whole-cell membrane currents. J. Gen. Virol. 84, 173–181 (2003).

51. Rashad, A. A. & Keller, P. A. Structure based design towards the identification of novel binding sites and inhibitors for the chikungunya virus envelope proteins. J. Mol. Graph. Model. 44, 241–252 (2015).

52. Jose, J., Snyder, J. E. & Kuhn, R. J. A structural and functional perspective of alphavirus replication and assembly NIH Public Access. Future. Microbiol. 4, 837–856 (2009).

53. Kielian, M., Chanel-Vos, C. & Liao, M. Alphavirus entry and membrane fusion. Viruses 2, 796–825 (2010).

54. Sánchez-San Martín, C., Sosa, H. & Kielian, M. A Stable prefusion intermediate of the alphavirus fusion protein reveals critical features of class II membrane fusion. Cell Host Microbe 4, 600–608 (2008).

55. Oliveira, D. M. de et al. Organometallic complex strongly impairs chikungunya virus entry to the host cells. Front. Microbiol. 11, (2020).

56. Schneidman-Duhovny, D., Inbar, Y., Nussinov, R. & Wolfson, H. J. PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Res. 33, W363–W367 (2005).

57. Andrussier, N., Nussinov, R. & Wolfsen, H. J. FireDock: Fast interaction refinement in molecular docking. Proteins Struct. Funct. Bioinforma. 69, 139–159 (2007).

58. Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778–2786 (2011).
